Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Drug Information and Pharmacotherapy
DI-078
ECONOMIC IMPACT EVALUATION OF OSELTAMIVIR ADJUSTMENT CRITERIA IN RENAL IMPAIRMENT
DI-077
EFFECTIVENESS AND SAFETY OF BIOSIMILAR INFLIXIMAB IN ULCERATIVE COLITIS
DI-075
EVALUATION OF THE EFFECTIVENESS AND SAFETY OF PIRFENIDONE AND NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS
DI-073
EXCIPIENTS IN PATIENTS WITH HEREDITARY FRUCTOSE INTOLERANCE
DI-071
INVITRO COMPARISON OF ANTACID DRUGS: APPLICATION TO SIX MARKETED FORMULATIONS
DI-069
COMPLIANCE OF ADOLESCENTS TO THE TREATMENT OF ACNE VULGARIS
DI-068
CHROMATOPSIA AND NIGHT BLINDNESS IN A PATIENT ON CAPECITABINE AND TEMOZOLOMIDE
DI-067
ANALYSIS OF THE USE OF TERIFLUNOMIDE IN A TERTIARY HOSPITAL
DI-066
PERMEATION ENHANCERS: EXCIPIENTS TO BE CONSIDERED IN TOPICAL FORMULATIONS WITH SYSTEMIC ADVERSE EFFECTS
DI-064
STUDY CONCERNING ADVERSE DRUG REACTIONS IN ADULT PATIENTS FROM SURGICAL WARDS IN A CLINICAL EMERGENCY HOSPITAL
DI-063
SURVIVAL BENEFIT WITH VEMURAFENIB IN ‘BRAF’ MUTATION POSITIVE MELANOMA: AREA UNDER THE CURVE BASED REANALYSIS
DI-062
SUSTAINED VIROLOGIC RESPONSE RATES OF NEW DIRECT ACTING ANTIVIRAL AGENTS FOR HCV
DI-060
TRANSLATING INTO ENGLISH A NEW TOOL TO GUIDE DEPRESCRIBING: A CROSS CULTURAL ADAPTATION
DI-059
USE OF DIMETHYL FUMARATE IN A TERTIARY HOSPITAL
DI-058
USE OF OMALIZUMAB IN A TERTIARY LEVEL HOSPITAL
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
Follow Us